Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q3 2025 · 10-Q
Revenue$348.54M$348.54M+3.7% vs Q3 2024 Net Income$37.49M$37.49M+20.0% vs Q3 2024 EPS Diluted$0.74$0.74+21.3% vs Q3 2024 Gross Profit$193,547,000+8.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$43,766,000N/M Free Cash Flowderived$35,220,000N/M Margins · derivedGross margin55.5%+2.6 pt vs Q3 2024
Operating margin16.9%+3.3 pt vs Q3 2024
Net margin10.8%+1.5 pt vs Q3 2024
ended Dec 28, 2024 · filed Feb 6, 2025 · 40 d after period end